Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients

Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients
OncBioMune Pharmaceuticals will soon start a Phase 2 clinical trial of its investigational vaccine ProscaVax in people with early-stage prostate cancer. ProscaVax consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). [Cytokines are molecules that participate in immune responses.] The study (NCT03579654) intends

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *